264 related articles for article (PubMed ID: 24027430)
1. Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.
Jacob AG; O'Brien D; Singh RK; Comiskey DF; Littleton RM; Mohammad F; Gladman JT; Widmann MC; Jeyaraj SC; Bolinger C; Anderson JR; Barkauskas DA; Boris-Lawrie K; Chandler DS
Neoplasia; 2013 Sep; 15(9):1049-63. PubMed ID: 24027430
[TBL] [Abstract][Full Text] [Related]
2. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
[TBL] [Abstract][Full Text] [Related]
3. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.
Jacob AG; Singh RK; Comiskey DF; Rouhier MF; Mohammad F; Bebee TW; Chandler DS
PLoS One; 2014; 9(8):e104444. PubMed ID: 25105592
[TBL] [Abstract][Full Text] [Related]
4. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
5. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
Fan C; Wang X
Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
[TBL] [Abstract][Full Text] [Related]
6. Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage.
Comiskey DF; Jacob AG; Singh RK; Tapia-Santos AS; Chandler DS
Nucleic Acids Res; 2015 Apr; 43(8):4202-18. PubMed ID: 25845590
[TBL] [Abstract][Full Text] [Related]
7. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines.
Bartel F; Taylor AC; Taubert H; Harris LC
Oncol Res; 2001; 12(11-12):451-7. PubMed ID: 11939408
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and MDM4 splicing: an integral part of the cancer spliceome.
Jeyaraj S; O'Brien DM; Chandler DS
Front Biosci (Landmark Ed); 2009 Jan; 14(7):2647-56. PubMed ID: 19273224
[TBL] [Abstract][Full Text] [Related]
9. Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress.
Singh RK; Tapia-Santos A; Bebee TW; Chandler DS
Exp Cell Res; 2009 Nov; 315(19):3419-32. PubMed ID: 19631207
[TBL] [Abstract][Full Text] [Related]
10. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
11. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma.
Ragazzini P; Gamberi G; Pazzaglia L; Serra M; Magagnoli G; Ponticelli F; Ferrari C; Ghinelli C; Alberghini M; Bertoni F; Picci P; Benassi MS
Histol Histopathol; 2004 Apr; 19(2):401-11. PubMed ID: 15024701
[TBL] [Abstract][Full Text] [Related]
12. Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.
Fernandez K; Serinagaoglu Y; Hammond S; Martin LT; Martin PT
Am J Pathol; 2010 Jan; 176(1):416-34. PubMed ID: 20019182
[TBL] [Abstract][Full Text] [Related]
13. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
[TBL] [Abstract][Full Text] [Related]
14. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
15. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
Kriegmair MC; Balk M; Wirtz R; Steidler A; Weis CA; Breyer J; Hartmann A; Bolenz C; Erben P
Anticancer Res; 2016 Oct; 36(10):5205-5213. PubMed ID: 27798881
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells.
Zhang M; Zhu B; Davie J
J Biol Chem; 2015 Jan; 290(1):310-24. PubMed ID: 25404735
[TBL] [Abstract][Full Text] [Related]
17. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
[TBL] [Abstract][Full Text] [Related]
18. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
20. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]